Viking Therapeutics (VKTX) Treasury Shares (2014 - 2026)
Viking Therapeutics (VKTX) posted Treasury Shares of $1.8 million for Q2 2026, little changed sequentially from $1.8 million in Q1 2026, and down 21.09% YoY from $2.3 million in Q2 2025.
Viking Therapeutics (VKTX) Treasury Shares (2014 - 2026) Analysis & Trends
Viking Therapeutics has reported Treasury Shares for 13 years, with the latest figure at $1.8 million in Q2 2026.
- Quarterly Treasury Shares changed 0.0% year-over-year to $6.8 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $6.8 million (changed 0.0% YoY) and the FY2023 annual result came in at $6.8 million, changed 0.0% from the prior year.
- Treasury Shares steadied at $6.8 million in Q4 2023 per VKTX's latest filing, from $6.8 million in the prior quarter.
- Over five years, Treasury Shares peaked at $6.8 million in Q3 2022 and troughed at $1.7 million in Q2 2022.
- A 5-year average of $2.4 million and a median of $2.3 million in 2025 frame the typical range for Treasury Shares.
- The sharpest annual moves came in 2022 and 2026: Treasury Shares jumped 127.92% in 2022, then dropped 21.09% in 2026.
- Over 2 years, Treasury Shares stood at $6.8 million in 2022, then changed by 0.0% to $6.8 million in 2023.
- According to Business Quant data, Treasury Shares over the past three periods registered $6.8 million, $6.8 million, and $6.8 million for Q4 2023, Q3 2023, and Q2 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 36.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 5.08 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.72 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 92,219.00 |
| 10 | Viking Therapeutics | 3.87 Bn | 3.87 Bn | - | 1.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.81 Mn |
| Jun 30, 2026 | 1.81 Mn |
| Mar 31, 2026 | 1.82 Mn |
| Mar 31, 2026 | 1.82 Mn |
| Dec 31, 2025 | 2.11 Mn |
| Dec 31, 2025 | 2.11 Mn |
| Sep 30, 2025 | 2.22 Mn |
| Sep 30, 2025 | 2.22 Mn |
| Jun 30, 2025 | 2.30 Mn |
| Jun 30, 2025 | 2.30 Mn |
| Mar 31, 2025 | 2.30 Mn |
| Mar 31, 2025 | 2.30 Mn |
| Dec 31, 2024 | 2.54 Mn |
| Dec 31, 2024 | 2.54 Mn |
| Sep 30, 2024 | 2.54 Mn |
| Sep 30, 2024 | 2.54 Mn |
| Jun 30, 2024 | 2.83 Mn |
| Jun 30, 2024 | 2.83 Mn |
| Mar 31, 2024 | 2.83 Mn |
| Mar 31, 2024 | 2.83 Mn |